These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 18347149)

  • 21. Antitumor properties of taxol in combination with cyclooxygenase-1 and cyclooxygenase-2 selective inhibitors on ovarian tumor growth in vivo.
    Li W; Zhai L; Tang Y; Cai J; Liu M; Zhang J
    Oncol Res; 2012; 20(2-3):49-59. PubMed ID: 23193911
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Engineered multifunctional biodegradable hybrid microparticles for paclitaxel delivery in cancer therapy.
    Dwivedi P; Han S; Mangrio F; Fan R; Dwivedi M; Zhu Z; Huang F; Wu Q; Khatik R; Cohn DE; Si T; Hu S; Sparreboom A; Xu RX
    Mater Sci Eng C Mater Biol Appl; 2019 Sep; 102():113-123. PubMed ID: 31146981
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Time course of Paclitaxel-induced apoptosis in an experimental model of virus-induced breast cancer.
    Erba PA; Manfredi C; Lazzeri E; Minichilli F; Pauwels EK; Sbrana A; Strauss HW; Mariani G
    J Nucl Med; 2010 May; 51(5):775-81. PubMed ID: 20395330
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Curcumin enhances oral bioavailability and anti-tumor therapeutic efficacy of paclitaxel upon administration in nanoemulsion formulation.
    Ganta S; Devalapally H; Amiji M
    J Pharm Sci; 2010 Nov; 99(11):4630-41. PubMed ID: 20845461
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Induction effect of rapamycin combined paclitaxel on apoptosis of ovarian cancer cell lines A2780 and SKOV3 and the molecular mechanism].
    Ma XY; Wang SX; Liu Y; Liu RH; Lu YP; Ma D
    Ai Zheng; 2007 Apr; 26(4):367-70. PubMed ID: 17430653
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy assessment of sustained intraperitoneal paclitaxel therapy in a murine model of ovarian cancer using bioluminescent imaging.
    Vassileva V; Moriyama EH; De Souza R; Grant J; Allen CJ; Wilson BC; Piquette-Miller M
    Br J Cancer; 2008 Dec; 99(12):2037-43. PubMed ID: 19034272
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Schedule-dependent paclitaxel tolerance/activity: data from a 7 day infusion phase I study with pharmacokinetics in paclitaxel refractory ovarian cancer.
    Soulié P; Trandafir L; Taamma A; Lokiec F; Brain E; Delord JP; Mita A; Vannetzel JM; Cvitkovic E; Misset JL
    Anticancer Drugs; 1997 Sep; 8(8):763-6. PubMed ID: 9396620
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Retention of paclitaxel in cancer cells for 1 week in vivo and in vitro.
    Mori T; Kinoshita Y; Watanabe A; Yamaguchi T; Hosokawa K; Honjo H
    Cancer Chemother Pharmacol; 2006 Nov; 58(5):665-72. PubMed ID: 16534615
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Enhanced paclitaxel cytotoxicity and prolonged animal survival rate by a nonviral-mediated systemic delivery of E1A gene in orthotopic xenograft human breast cancer.
    Liao Y; Zou YY; Xia WY; Hung MC
    Cancer Gene Ther; 2004 Sep; 11(9):594-602. PubMed ID: 15272313
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Docetaxel in ovarian cancer: phase III perspectives and future development.
    Kaye SB; Vasey PA
    Semin Oncol; 2002 Jun; 29(3 Suppl 12):22-7. PubMed ID: 12170448
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ovarian cancer targeted hyaluronic acid-based nanoparticle system for paclitaxel delivery to overcome drug resistance.
    Wang L; Jia E
    Drug Deliv; 2016 Jun; 23(5):1810-7. PubMed ID: 26530693
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A case of chronic paclitaxel administration in ovarian cancer.
    von Gruenigen VE; Karlen JR; Waggoner SE
    Gynecol Oncol; 2003 Jun; 89(3):532-5. PubMed ID: 12798725
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antivascular therapy for orthotopic human ovarian carcinoma through blockade of the vascular endothelial growth factor and epidermal growth factor receptors.
    Thaker PH; Yazici S; Nilsson MB; Yokoi K; Tsan RZ; He J; Kim SJ; Fidler IJ; Sood AK
    Clin Cancer Res; 2005 Jul; 11(13):4923-33. PubMed ID: 16000591
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Sperm associated antigen 9 (SPAG9) a promising therapeutic target of ovarian carcinoma.
    Jagadish N; Fatima R; Sharma A; Devi S; Suri V; Kumar V; Suri A
    Tumour Biol; 2018 May; 40(5):1010428318773652. PubMed ID: 29745297
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Multifunctional Polymeric Micelles Co-loaded with Anti-Survivin siRNA and Paclitaxel Overcome Drug Resistance in an Animal Model of Ovarian Cancer.
    Salzano G; Navarro G; Trivedi MS; De Rosa G; Torchilin VP
    Mol Cancer Ther; 2015 Apr; 14(4):1075-84. PubMed ID: 25657335
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Inhibition of phosphatidylinositol 3'-kinase increases efficacy of paclitaxel in in vitro and in vivo ovarian cancer models.
    Hu L; Hofmann J; Lu Y; Mills GB; Jaffe RB
    Cancer Res; 2002 Feb; 62(4):1087-92. PubMed ID: 11861387
    [TBL] [Abstract][Full Text] [Related]  

  • 37. ZD4054, a specific antagonist of the endothelin A receptor, inhibits tumor growth and enhances paclitaxel activity in human ovarian carcinoma in vitro and in vivo.
    Rosanò L; Di Castro V; Spinella F; Nicotra MR; Natali PG; Bagnato A
    Mol Cancer Ther; 2007 Jul; 6(7):2003-11. PubMed ID: 17620430
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The vascular targeting property of paclitaxel is enhanced by SU6668, a receptor tyrosine kinase inhibitor, causing apoptosis of endothelial cells and inhibition of angiogenesis.
    Naumova E; Ubezio P; Garofalo A; Borsotti P; Cassis L; Riccardi E; Scanziani E; Eccles SA; Bani MR; Giavazzi R
    Clin Cancer Res; 2006 Mar; 12(6):1839-49. PubMed ID: 16551869
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clindamycin-paclitaxel pharmacokinetic interaction in ovarian cancer patients.
    Fruscio R; Lissoni AA; Frapolli R; Corso S; Mangioni C; D'Incalci M; Zucchetti M
    Cancer Chemother Pharmacol; 2006 Sep; 58(3):319-25. PubMed ID: 16362296
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Paclitaxel-loaded hyaluronan solid nanoemulsions for enhanced treatment efficacy in ovarian cancer.
    Kim JE; Park YJ
    Int J Nanomedicine; 2017; 12():645-658. PubMed ID: 28176896
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.